Cell Therapeutics has eliminated 34 jobs in connection with the sale of its lone approved drug, Zevalin. The Seattle-based biotech company (NASDAQ: [[ticker:CTIC]]), which has run dangerously low on cash, made the disclosure Friday afternoon in a filing with the Securities and Exchange Commission. The cuts represent about 28 percent of the company’s workforce, and leave it with about 88 employees.
For an updated list of layoffs at Seattle-area technology and life sciences companies, click here.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
